(S1 (S (S (NP (NP (NN Selection)) (PP (IN of) (NP (NP (JJ novel) (NNS mediators)) (PP (IN of) (NP (JJ E2F1-induced) (NN apoptosis))))) (PP (IN through) (NP (NP (JJ retroviral) (NN expression)) (PP (IN of) (NP (DT an) (JJ antisense) (NN cDNA) (NN library))))))) (. .)))
(S1 (S (S (NP (DT The) (NN E2F1) (NN transcription) (NN factor)) (VP (VBZ is) (NP (NP (DT an) (JJ essential) (NN mediator)) (PP (IN of) (NP (ADJP (ADJP (JJ p53-dependent)) (CC and) (ADJP (JJ p53-independent))) (NN apoptosis)))) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (DT an) (JJ anti-tumour) (VBP safeguard) (NN mechanism))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (DT a) (JJ functional) (JJ so-called) (JJ technical) (JJ knockout) (-LRB- -LRB-) (NN TKO) (-RRB- -RRB-) (NN approach)) (VP (VBD was) (VP (VBN applied) (PP (TO to) (NP (NP (NN Saos-2ERE2F1) (NNS cells)) (SBAR (WHNP (WDT that)) (S (ADVP (RB conditionally)) (VP (VBP activate) (NP (NN E2F1)) (PP (IN by) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NN 4-hydroxytamoxifen))) (S (VP (TO to) (VP (VB search) (PP (IN for) (NP (JJ p53-independent) (JJ pro-apoptotic) (NN E2F1) (NNS targets)))))))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN approach)) (VP (VBD was) (VP (VBN based) (PP (IN on) (NP (NP (JJ random) (NN inactivation)) (PP (IN of) (NP (NNS genes))) (PP (IN after) (NP (NP (JJ retroviral) (NN transfer)) (PP (IN of) (NP (NP (DT an) (JJ antisense) (NN cDNA) (NN library)) (VP (VBN enriched) (PP (IN of) (NP (JJ E2F1-induced) (NNS genes)))))))))) (, ,) (S (VP (VBN followed) (PP (IN by) (NP (NP (DT the) (NN selection)) (PP (IN of) (NP (NP (NN Saos-2ERE2F1) (NNS cells)) (SBAR (WHNP (WDT that)) (S (VP (VBP survive) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT the) (JJ apoptotic) (NN stimulus))))))))))))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD identified) (NP (NP (CD 13) (JJ novel) (NN E2F1) (NN target) (NNS genes)) (VP (VBG encoding) (NP (NP (NNS proteins)) (PP (IN of) (NP (JJ known) (JJ cellular) (NN function))))) (, ,) (PP (VBG including) (NP (NP (NN apoptosis)) (CC and) (NP (NN RNA) (NN binding))))))) (. .)))
(S1 (S (S (NP (NN FACS) (NN analysis)) (VP (VBD revealed) (SBAR (IN that) (S (NP (JJ E2F1-induced) (NN apoptosis)) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN attenuated) (PP (IN in) (NP (NP (NN cell) (NNS clones)) (VP (VBG containing) (NP (NP (DT the) (JJ antisense) (NN cDNA) (NNS fragments)) (PP (IN of) (NP (DT these) (NNS genes))))))) (, ,) (S (VP (VBG demonstrating) (NP (NP (PRP$ their) (NN participation)) (PP (IN in) (NP (NN E2F1) (NN death) (NNS pathways)))))))))))) (. .)))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (NP (NN inactivation)) (PP (IN of) (NP (DT the) (NN target) (NNS genes)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ clear) (NN increase)) (PP (IN of) (NP (NN cell) (NN viability))))) (PRN (-LRB- -LRB-) (NP (NN >) (CD 80) (NN %)) (-RRB- -RRB-)) (PP (IN in) (NN response) (TO to) (NP (NN E2F1) (NN activation))) (PP (VBN compared) (PP (IN with) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (QP (RB approximately) (CD 30)) (NN %)) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (CD Four) (NNS genes)) (VP (VBD showed) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN expression) (NN intensity))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN cycloheximide)))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT a) (JJ direct) (NN effect)) (PP (IN of) (NP (NN E2F1))) (PP (IN on) (NP (NN gene) (NN transcription)))))) (, ,) (SBAR (IN whereas) (S (NP (CD one) (NN gene)) (VP (VBD was) (VP (VBN identified) (PP (IN as) (NP (DT an) (JJ indirect) (NN target))))))))) (. .)))
(S1 (S (S (NP (PRP$ Our) (NNS data)) (VP (VBP provide) (NP (NP (JJ new) (NN insight)) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (JJ E2F1-induced) (NN apoptosis)))))))) (. .)))
